Rapidly evolving and ever-increasing knowledge of the molecular pathophysiology of pancreatic cancer has leveraged our understanding altogether to a next level. Compared to the exciting ground-breaking discoveries related to underlying mechanisms of pancreatic cancer onset and progression, however, there had been relatively few advances in the therapeutic options available for the treatment. Since the discovery of the DNA structure as a helix which replicates semi-conservatively to pass the genetic material to the progeny, there has been conceptual refinement and continuous addition of missing pieces to complete the landscape of central dogma. Starting from transcription to translation, modern era has witnessed non-coding RNA discovery and central role of these versatile regulators in onset and progression of pancreatic cancer. Long non-coding RNAs (lncRNAs) have been shown to act as competitive endogenous RNAs through sequestration and competitive binding to myriad of microRNAs in different cancers. In this article, we set spotlight on emerging evidence of regulation of different signaling pathways (Hippo, TGFβ/SMAD, Wnt/β-Catenin, JAK/STAT and NOTCH) by lncRNAs. Conceptual refinements have enabled us to understand how lncRNAs play central role in post-translational modifications of various proteins and how lncRNAs work with epigenetic-associated machinery to transcriptionally regulate gene network in pancreatic cancer.

**Keywords:** lncRNA, apoptosis, signaling pathways, microRNA, pancreatic cancer

**INTRODUCTION**

It has been reported that only 1–2% of RNAs encode for proteins and that the great majority of them falls into the non-coding category, comprehending a large number of different structural (ribosomal RNAs, rRNAs and transfer RNAs, tRNAs) and regulatory RNAs (small conditional RNAs, scRNAs; microRNAs, miRNAs; small nucleolar RNAs, snoRNAs; long non-coding RNAs, IncRNAs) (1).
Regulatory RNAs can be divided into small, medium, and long non-coding RNAs (2). LncRNAs sequences are poorly conserved and thus their genomic identification results often difficult (3). They are defined as long RNA transcripts (> 200 nucleotides) not translated in proteins (4), which are involved in the regulation of transcriptional processes by modulation of other non-coding RNAs (ncRNAs) (5). These nucleic acids are responsible also for regulating gene expression at transcriptional and post-transcriptional levels (6, 7). Even though largely debated, recent studies performed exploiting ribosome sequencing (Ribo-seq) and mass spectrometry have revealed their possible translation into proteins (8). Many researches have focused on unraveling the functions of ncRNAs and a careful classification based on their characterization has been established. In recent years, thanks to RNA sequencing and innovative methods, a great number of categories have been identified (9).

LncRNAs can originate from their own/shared promoters, from enhancers and intergenic regions and in specific cell-types upon stimuli. For example, human pancreatic β-cells contain thousands of lncRNAs that can be controlled during differentiation, maturation and upon glucose dynamic changes and are responsible for regulating gene expression in diabetes. Although their function is still under investigation, many techniques have been used for unraveling lncRNAs intracellular localization, structure and functions (10–12).

Different mechanisms that are involved in their biogenesis and peculiar subnuclear structures, called paraspeckles, have been identified. They localize in proximity of nuclear enriched abundant transcript 1 (NEAT1) lncRNAs, specific transcripts lacking introns. Recent studies identified four paraspeckle proteins required for their formation during NEAT1 synthesis and processing. Importantly, paraspeckles have been also involved in modulation of gene expression mediated by lncRNAs (13).

Interestingly, lncRNAs can be transcribed by many regions in the genome, including promoters, enhancers or long primary transcripts. Processing of lncRNAs can be carried out by ribonuclease P for generating mature 3′ ends capped by small nucleolar RNA-proteins or by formation of circular structures (14). LncRNAs can be transcribed as promoter upstream transcripts (PROMPTs) (15), enhancer RNAs (eRNAs) (16), long intervening/intergenic ncRNAs (lincRNAs) (17). When they are transcribed by RNA polymerase II (Pol II), they are produced as medium length lncRNAs with short half-life and targeted by a special nuclear degradation complex called RNA exosome. This process put their gene regulatory activity at high risk.

The most studied category of lncRNAs is lincRNAs, transcribed by Pol II from intergenic regions. These transcripts contain multiple exons and similarity to mRNAs (18), even though they present very different features: they do not possess encoding sequences, they present tissue specific expression, localize at the nucleus and have specific functions (19, 20). Other lncRNAs transcribed from the natural antisense transcripts called NATs (21).

Recently, it has been shown that lincRNAs present few histone marks and transcription factors attached to their promoters and are less spliced respect to mRNAs (22). Interestingly, some lncRNAs can be processed from long transcripts to obtain structures without 5′ cap or 3′ adenosine tails (23).

LncRNAs are involved in the transcription modulation mediated by control of gene expression by attaching to DNA binding proteins and Pol II. They can interfere with many cellular mechanisms, such as cell proliferation, differentiation and development (5). Interestingly, they have been demonstrated to be associated to tumorigenesis, when mutated or dysregulated. They are involved in the onset of many types of tumors, such as colorectal, lung, liver, pancreatic, and ovarian cancer (24, 25). Some studies have shown their involvement in several diseases (26).

To provide a comprehensive overview of the interplay between lncRNAs and signaling pathways in pancreatic cancer, we have partitioned this article into three sections. In the first section, we focus on the elucidation of the molecular mechanisms used by lncRNAs to modulate signaling pathways in pancreatic cancer. This section exclusively deals with regulation of Hippo, TGFβ/SMAD, Wnt/β-catenin, Notch, JAK/STAT and TRAIL-driven pathways by lncRNAs in pancreatic cancer. In the second section, we provided a list of individual lncRNAs reportedly involved in the regulation of protein networks in pancreatic cancer. In the last section, we outlined the list of lncRNAs which served as sponges for miRNAs and sequestered target mRNAs away from inhibition by miRNAs.

MECHANISM BASED REGULATION OF PANCREATIC CANCER BY LncRNAs

LncRNAs mediated regulation of pancreatic cancer is highly intricate. Different proteins have been shown to regulate expression of lncRNAs. Likewise, lncRNAs have been reported to work with methylation specific machinery to activate or repress myriad of genes. Moreover, lncRNAs have also been noted to regulate post-translational modifications of different proteins. In this section, we exclusively focus on regulation of Hippo, TGFβ/SMAD, Wnt/β-catenin, Notch, JAK/STAT and TRAIL-driven pathways by lncRNAs in pancreatic cancer.

Regulation of Hippo Pathway by Long Non-Coding RNAs

When the Hippo pathway is activated, LATS1/2 kinases (Large tumor suppressor-1/2) phosphorylate and inactivate YAP (Yes-associated protein) and transcriptional coactivator having PDZ-binding motifs (TAZ), the two characteristically unique downstream transducers that mediate transcriptional output of the Hippo-driven transcription cascade. Phosphorylation of YAP at 127th serine residue by LATS1 is a classical post-translational modification which induces cytoplasmic retention of YAP to inhibit its activity (27). THAP9-AS1 knockdown resulted in an increase in the phosphorylation of YAP at 127th serine residue.
THAP9-AS1 increased expression of YAP by sponging miRNA-484 away from YAP. Series of experiments revealed that WW1/2 domain of YAP was essential for direct interaction with LATS1 to induce phosphorylation and subsequent retention of YAP within cytoplasm (27) (Figure 1). THAP9-AS1 interacted with YAP and blocked LATS1-YAP association. Co-immunoprecipitation assays revealed that knockdown of THAP9-AS1 potentiated the interactions between LATS1 and YAP. Although YAP/TAZ are transcriptional co-activators, they do not have DNA-binding domains. Therefore, YAP/TAZ need binding partners and usually bind with transcriptional factors such as TEAD1-4 for modulation of expression of target genes. YAP/TEAD1 complex transcriptionally upregulated the expression of THAP9-AS1 (Figure 1) (27).

It is exciting to note that most of the lncRNAs (LINC01559 and UCA1) inhibit phosphorylation of YAP and promote its nuclear accumulation. LINC01559 interacted with YAP, inhibited YAP phosphorylation, and enhanced YAP-induced transcriptional activities in pancreatic cancer cells (28).

YAP1 maintained the expression of MYC, whereas knockout of YAP1 caused considerable downregulation of MYC that resulted in growth arrest of pancreatic cancer cells and apoptosis (29). Lnc-EPIC1 interacted with YAP1 in pancreatic cancer cells. Lnc-EPIC1 lost its ability to promote proliferation and growth of YAP1-silenced pancreatic cancer cells (29).

Likewise, UCA1 significantly enhanced the invasive ability of PANC-1 cells (30). LATS1/2 requires a co-activator protein to achieve full activation. MOB1 (Mps One binder 1) is essential for the activation of LATS1/2. UCA1, formed a complex with LATS1, MOB1 and YAP (Figure 1). UCA1 promoted nuclear translocation of YAP in PANC-1 cells. Additionally, YAP stimulated the expression of UCA1 in pancreatic cancer cells (30). Overall, UCA1 and YAP promoted invasion of pancreatic cancer cells.

These interesting findings provided substantial evidence that different lncRNAs inhibited YAP phosphorylation and potentiated YAP-driven signaling to promote pancreatic cancer. MST1 and MST2 promoted the phosphorylation of LATS1 and LATS2 (31). MST1 was found to be directly targeted by miR-181c-5p. miR-181c-5p promoted chemoresistance of pancreatic cancer cells through inactivation of the Hippo signaling. GAS5 interfered with miR-181c-5p-mediated inhibition of MST1 in pancreatic cancer cells. Tumor growth was significantly reduced in mice inoculated with GAS5-overexpressing PANC-1 cells (31).

### Regulation of TGFβ/SMAD Signaling

TGFβ/SMAD signaling has been shown to play significant role in the onset and progression of pancreatic cancer. Here we discuss how different lncRNAs regulate TGFβ/SMAD to promote pancreatic cancer.

Linc00462 considerably enhanced invasive potential of pancreatic cancer cells via stimulating the expression of TGFβ1 and TGFβ2 (32). TGFβ1 and TGFβ2 were found to be directly targeted by miR-665. However, Linc00462 sponged away miR-665 and relieved inhibitory effects of miR-665 on TGFβ1 and TGFβ2 (Figure 1). Linc00462 overexpression significantly increased p-SMAD2 and p-SMAD3 whereas, overexpression of miR-665 significantly decreased p-SMAD2 and p-SMAD3 (32).

PVT1 stimulated TGFβ/SMAD signaling that sequentially induced epithelial-to-mesenchymal transition (EMT) (32). PVT1 silencing resulted in inactivation of TGFβ/SMAD.
signaling via reduction of p-SMAD2/3 and TGFβ1 but there was a notable increase in the levels of SMAD4 (32).

DLEU2 blocked miR-455-mediated targeting of SMAD2 in pancreatic cancer cells (Figure 1) (33). SMAD2 promoted invasive potential of pancreatic cancer cells. miR-455 overexpression or DLEU2 knockdown significantly suppressed proliferation and invasion of MIA PaCa-2 cells. Similarly, miR-455 inhibition or DLEU2 overexpression significantly induced proliferation and invasion in AsPC-1 cells, whereas SMAD2 inhibition markedly reversed the effects of miR-455 inhibition or DLEU2 overexpression (33).

Collectively, these research reports highlighted oncogenic interplay between lncRNAs and TGFβ/SMAD pathway to promote pancreatic cancer.

**LncRNA-Mediated Regulation of Wnt/β-Catenin Signaling**

FZD4 and FZD6 played a central role in activation of Wnt/β-catenin pathway. miR-497-5p targeted FZD4 and FZD6 and inhibited Wnt/β-catenin transduction cascade (34). DLX6-AS1 interfered with miR-497-5p-mediated targeting of FZD4 and FZD6 (Figure 2). DLX6-AS1 knockdown inhibited the metastatic capacity of pancreatic cancer cells by reducing the number of metastatic foci in the liver and lungs. However, DLX6-AS1 overexpression considerably enhanced the metastatic foci in the liver and lungs of xenografted mice (34). Overall, these results indicated that DLX6-AS1 acted as an oncogenic lncRNA and potentiated Wnt/β-catenin signaling.

Lnc00261 inhibited the activation of the β-catenin/TCF4 pathway and cell metastasis by blocking miR-552-5p-induced targeting of FOXO3 in pancreatic cancer cells (35). β-catenin and TCF4 were noted to be reduced in Lnc00261-overexpressing pancreatic cancer cells. There was a negative relationship of FOXO3 and β-catenin/TCF4 in pancreatic cancer cells. The number of metastatic foci was reduced in the mice injected with the Lnc00261-expressing PANC-1 cells (35).

TSLNC8 worked jointly with HuR and promoted the binding of HuR to β-catenin mRNA to stabilize β-catenin, thus activating WNT/β-catenin transduction cascade (Figure 2) (36).
HOTAIR inhibition increased the expression of WIF-1 (Wnt inhibitory factor 1) and enhanced radiosensitivity of pancreatic cancer cells (37).

LINC01197 physically associated with β-catenin and inhibited Wnt/β-catenin signaling cascade in PANC1 and BxPC3 cancer cells (Figure 2) (38). LINC01197 disassembled β-catenin and TCF4 in BxPC3 and PANC1 cells. LINC01197 overexpression inhibited the binding of β-catenin and TCF4 both in BxPC3 and PANC1 cells. LINC01197 overexpression induced significant inhibition of the growth of the tumors derived from BxPC3- and PANC1 cancer cells (38).

DKK1 is a soluble inhibitor of Wnt/β-catenin cascade that can bind to LRP5/6 and induce internalization of LRP proteins (39). LINC01133 promoted the loading of EZH2 to transcriptionally downregulate DKK1 in pancreatic cancer cells (Figure 2). Importantly, metastatic spread to the liver and lungs was reduced in mice inoculated with LINC01133-silenced pancreatic cancer cells (39).

**Regulation of NOTCH Signaling**

SNHG1 has been reported to be significantly upregulated in pancreatic cancer cells (40). NOTCH-induced oncogenic pathway was also noted to be active in pancreatic cancer cells. SNHG1 knockout exerted inhibitory effects on the activation of the NOTCH-driven signaling pathway and inhibited the expression of NOTCH-1, HES1, vimentin, and N-cadherin (40).

Levels of Jagged-1, HES1, HES5 were noted to be markedly reduced in RP11-567G11.1-depleted PANC-1 and BXPC-3 cells (41). Overall, these findings provided evidence that different long non-coding RNAs effectively potentiated NOTCH-driven pathway in the pancreatic cancer cells.

NOTCH3 is negatively regulated by miR-613 in pancreatic cancer cells (42). HOTAIR sequestered away miR-613 and potentiated NOTCH3 expression. miR-613 overexpression or knockdown of HOTAIR suppressed tumor growth and also reduced the expression of NOTCH3 (42).

**Regulation of JAK/STAT Signaling**

STAT1-mediated transduction cascade played critical role in the progression of pancreatic cancer (43). miR-382-3p exerted tumor suppressive effects and directly targeted STAT1. However, PSMB8-AS1 interfered with miR-382-3p-mediated inhibition of STAT1. There was a significant increase in the growth of tumors in experimental mice xenografted with PSMB8-AS1-overexpressing PANC-1 cells. STAT1 and PD-L1 were found to be upregulated in mice xenografted with PSMB8-AS1-overexpressing PANC-1 cells (43).

H19, an oncogenic lncRNA effectively promoted STAT3-mediated signaling in pancreatic cancer cells (44). miR-675 is transcribed from the first exon of H19 and negatively regulates SOCS5 (Suppressor of cytokine signaling 5). SOCS5 is involved in the inhibition of STAT3-driven signaling. It was found that miR-675 negatively modulated SOCS5 and potentiates the expression of STAT3. H19 upregulation reduced gemcitabine chemosensitivity and lowered apoptosis in CAPAN-1 cells. However, gemcitabine chemosensitivity and the apoptosis rate were significantly increased in H19-silenced PANC-1 cells (44).

**Regulation of TRAIL-Mediated Signaling**

Cell surface expression of death receptors (DR4 and DR5) is of critical importance to achieve therapeutic effects of TRAIL-based therapeutics.

HOTAIR worked synchronously with EZH2 and transcriptionally downregulated DR5 in pancreatic cancer cells (45). HOTAIR inhibited DR5 transcription by enhancing EZH1-induced histone H3 trimethylation on DR5 gene. HOTAIR knockdown in the TRAIL-resistant PANC-1 cancer cells restored apoptotic cell death (45).

**MECHANISTIC INTERPLAY BETWEEN LncRNAs AND PROTEINS IN PANCREATIC CANCER**

Here we provided a list of lncRNAs reportedly involved in the regulation of myriad of proteins in pancreatic cancer.

**PLACT1**

PLACT1 an oncogenic lncRNA has been described to repress 1xBz expression mainly through increased loading of hnrNPA1 to promoter region of 1xBz (46). Additionally, there was an evident increase in the trimethylated levels of lysine 27 of histone-3 that also played role in epigenetic inactivation of 1xBz (Figure 3). E2F1-mediated stimulation of PLACT1 fueled progression of PDAC by sustained activity of NF-κB cascade. Expectedly, use of NF-κB signaling inhibitors caused significant suppression of PLACT1-induced sustained NF-κB activity that consequently induced regression of tumors in xenografted mice (46).

**HOTTIP**

HOTTIP (HOXA transcript at the distal tip) formed a complex with adaptor protein WDR5 and MLL1 (H3K4 methyltransferase) to trans-activate oncogenic proteins CYB5R2, KIF26A, SULT1A1, TSC22D1, and SLC1A4 by increasing the levels of trimethylated lysine-4 at histone-3 (H3K4) at their promoters (Figure 3) (47). Collectively, these findings provided concrete evidence of fundamental role of HOTTIP in promotion of PDAC progression through the HOTTIP–WDR5–MLL1 axis.

**SLC7A11-AS1**

SLC7A11-AS1 promoted chemoresistance through reduction of intracellular ROS by stabilizing NRF2 (nuclear factor erythroid-2-related factor 2) (48). Proteomic studies revealed that SLC7A11-AS1 co-localized with β-TRCP1 in the nucleus. β-TrCP, an F-box protein served as substrate-recognition subunit for the SCFβ-TrCP E3 ubiquitin ligase, which mediated ubiquitylation of a broad range of substrates and post-translationally marked proteins.
for degradation. A series of experiments revealed that exon 3 of SLC7A11-AS1 interacted with the F-box motif of β-TRCP1. The F-box motif of β-TRCP1 acted as a critical domain that recruited β-TRCP1 to the SCFβ-TRCP E3 complex. Resultantly, this interaction prevented ubiquitination and degradation of NRF2 in the nucleus. SLC7A11-AS1 overexpression blocked SCFβ-TRCP-induced ubiquitination and degradation of NRF2 and effectively reduced intracellular levels of ROS (Figure 3) (48).

**SOX2OT**

SOX2OT fueled proliferation capacity of PDAC cells by binding directly to FUS and destabilizing the FUS protein (Figure 3). SOX2OT upregulated the proliferation of the BxPC-3 and PANC-1 cells. FUS transcriptionally repressed CCND1 in pancreatic cancer cells (49).

**Interplay Between DANCR and IGF2BP2**

N6-methyladenosine (m6A) has been shown to tag wide-ranging messenger RNAs in mammalian cells. Molecular studies had shown that m6A modification machinery consisted of “writers”, “erasers”, and “readers” (50). The YTH domain family (YTHDF) and IGF2BPs belonged to large families of RNA-binding proteins (RBPs) and served as readers. IGF2BPs served as a specialized family of m6A readers that targeted various mRNA transcripts. IGF2BPs stabilized and stored mRNAs marked by m6A during stress and normal situations (50). IGF2BP2 promoted pancreatic cancer cell proliferation. DANCR expression was upregulated in IGF2BP2-overexpressing cancer cells. Moreover, knockdown of IGF2BP2 suppressed DANCR expression. DANCR knockdown suppressed cell proliferation and colony formation. IGF2BP2 interacted with DANCR and stabilized it effectively. RNA methylation (m6A) occurred at 664th nucleotide of DANCR. Methylated DANCR was recognized by IGF2BP2 and resultantly, IGF2BP2 served as a reader for the methylated version of DANCR and increased its stability (50).

**LINC01111**

LINC01111 acted as a tumor suppressor lncRNA in pancreatic cancer. LINC0111 knockdown enhanced cell proliferation,
invasion, and migration in vitro (51). Tumor growth was found to be significantly enhanced in mice xenografted with LINC01111-silenced pancreatic cancer cells. Higher expression levels of LINC01111 relieved repressive effects of miR-3924 on DUSP1 and effectively blocked SAPK phosphorylation and thus inactivated SAPK/JNK signaling pathway in pancreatic cancer cells. Shown in Figure 3. DUSP1 (Dual-specificity phosphatase-1) is reportedly involved in dephosphorylation of different proteins. Therefore, DUSP1-mediated dephosphorylation of SAPK resulted in inhibition of the pathway (Figure 3). Functional studies had shown that phosphorylation activated function of SAPK/JNKs. SAPK/JNKs translocated from the cytoplasm to the nucleus where they phosphorylated series of genes including c-Jun, ATF2, etc. and dramatically enhanced their transcriptional activities (51). MACC1-AS1 knockdown inhibited the proliferation as well as metastasizing capacity of pancreatic cancer cells. MACC1-AS1 overexpressing pancreatic cancer cells demonstrated significantly increased mobility of cancer cells (53, 54). MACC1-AS1 stabilized protein levels of pyruvate kinase M2. NOTCH1 phosphorylation was increased in MACC1-AS1-overexpressing pancreatic cancer cells. However, phosphorylation was blocked in pyruvate kinase M2-knockdown cancer cells (53, 54). Overall, these findings suggested that MACC1-AS1 potentiated pyruvate kinase M2-driven phosphorylation of NOTCH1 (Figure 4). Oncogenic NOTCH1 pathway was activated by MACC1-AS1 through pyruvate kinase M2 in the pancreatic cancer cells.

**AGAP2-AS1**

RREB1-binding sites have been identified in the promoter region of AGAP2-AS1 and consequently could binding of RREB1 to the promoter region of AGAP2-AS1 stimulated its expression (52). AGAP2-AS1 worked synchronously with EZH2 (enhancer of zeste homolog-2) and epigenetically inhibited ANGPTL4 and ANKRD1 and fueled proliferation and metastasis of pancreatic cancer cells (52). Shown in Figure 3.

**XLOC_006390**

Overexpression of XLOC_006390 promoted the protein stability of c-Myc by blocking its ubiquitination. c-Myc transcriptionally upregulated glutamate dehydrogenase-1 in pancreatic cancer cells (53, 54). Collectively, XLOC_006390 promoted pancreatic carcinogenesis and glutamate metabolism by stabilization of c-Myc (53, 54).

**LINC01638**

LINC01638 overexpression promoted, while LINC01638 silencing inhibited migratory and invasive potential of PDAC cell line (55, 56). LINC01638 overexpression increased TGFβ1, while silencing of LINC01638 markedly reduced TGFβ1 expression in pancreatic ductal adenocarcinoma cell line (55, 56).

**MACC1-AS1**

MACC1-AS1 acted an oncogenic lncRNA and potentiated the expression of SMAD2 by sequestering it away from miR-145 (57, 58). In turn, SMAD2 stimulated the expression of MACC1-AS1 by directly binding to the promoter. Overall, these results clearly suggested that MACC1-AS1 promoted cancer by potentiating SMAD-driven signaling.

**PCTST**

lnc-PCTST, a tumor suppressor lncRNA increased E-cadherin and simultaneously reduced vimentin levels (57, 58). Additionally, TACC-3 knockdown also induced an increase in the levels of E-cadherin. Functional studies revealed that Inc-PCTST was closely associated with its genomic neighboring gene TACC-3 and considerably reduced its promoter activity (57, 58).

**MTA2TR**

Metastasis associated protein 2 (MTA2) transcriptional regulator lncRNA (MTA2TR) worked synchronously with ATF3 (activating transcription factor-3) and transcriptionally upregulated the expression of MTA2 (55, 56). MTA2 stabilized HIF-1α protein via deacetylation and promoted HIF-1α-induced transcriptional upregulation of MTA2TR (56). Shown in Figure 4. Overall, these results highlighted intricate role of MTA2TR in stabilization of HIF-1α via MTA2 in pancreatic cancer cells.

**HOXA-AS2**

Detailed mechanistic insights revealed that HOXA-AS2 interacted directly with EZH2 (enhancer of zeste homolog-2) and lysine specific demethylase 1 (LSD1) and synchronously promoted growth ability of pancreatic cancer cells (59).

**KCNK15-AS1**

KCNK15-AS1 markedly reduced migratory and invasive potential of BxPC-3 and MIA PaCa-2 cells (60). KCNK15-AS1 m6A enrichment was noted to be significantly higher in BxPC-3 and MIA PaCa-2 cells. ALKBH5, a versatile RNA m6A demethylase efficiently demethylated KCNK15-AS1 in pancreatic cancer cells (60). Overall, these results indicated that ALKBH5-driven demethylation of KCNK15-AS1
dramatically reduced migratory and invasive potential of pancreatic cancer cells.

**BX111**

BX111 was transcriptionally stimulated by HIF-1α (hypoxia-inducible factor) in response to hypoxia (61). Furthermore, BX111 participated in hypoxia-driven EMT of pancreatic cancer cells by promoting the binding of Y-box protein (YB1) to promoter region of ZEB1 (Figure 4) (61).

**HOTAIR**

HOTAIR is an oncogenic lncRNA and increased expression of HOTAIR is indicative of a poor prognosis in cancer patients (62). Although its exact role is not fully understood, several studies have revealed some of its functions in pancreatic cancer. A recent study (63) showed that HOTAIR serves as up-stream regulator of HK2, an enzyme that catalyzes the first step of glycolysis (64) and thus boosting cancer cell proliferation in pancreatic cancer cells. Its overexpression also increases both ATP and lactate production as well as glucose uptake. Additionally, increased HOTAIR levels downregulated death receptor 5 (DR5) and prevented TRAIL-mediated apoptosis. EZH2 effectively catalyzed histone H3 lysine 27 trimethylation (H3K27me3), an essential epigenetic modification on histone that controlled structure of the chromatin and epigenetically silenced target genes. HOTAIR knockdown markedly decreased H3K27me3 loading to the DR5 promoter, while HOTAIR overexpression greatly enhanced H3K27me3 loading to the DR5 promoter. HOTAIR worked synchronously with EZH2 and marked promoter of DR5 with H3K27me3 to epigenetically silence DR5 (45). Moreover, polymorphisms such as rs4759314 and rs200349340 increase HOTAIR expression and promote pancreatic cancer susceptibility (65, 66).

**MALAT1**

MALAT1 and EZH2 epigenetically inactivated E-cadherin and potently enhanced invasion and migration of pancreatic cancer cells (67). Importantly, histone methylation and DNA methylation are highly dynamic mechanisms centrally involved in the reprogramming of gene networks in wide variety of cellular processes. Different chemicals are currently being tested to inhibit polycomb repressive complexes to re-program gene networks (68, 69). Furthermore, knockdown of MALAT1 inhibited proliferation, migration, invasion as well as the expression of genes involved in EMT. Knockdown of MALAT1 also results in downregulation of Snail and Slug, two transcription factors that are related to EMT (70).

**Competing Endogenous RNA Activity of LncRNAs**

Wealth of information has portrayed competing endogenous RNA (ceRNA) activity as a large-scale regulatory network across the transcriptome which has greatly expanded the functional
genetic information in the human genome and played role in cancer onset and progression.

Linc00976 promoted proliferation, migration, and invasion by sequestering OTUD7B away from miR-137 in pancreatic cancer cells (71). OTUD7B, a deubiquitination enzyme efficiently deubiquitinated EGFR and activated downstream pathway. EGFR was considerably more stable in OTUD7B-overexpressing pancreatic cancer cells (71).

LOXL1-AS1 promoted pancreatic cancer by promoting the expression of Semaphorin 7A (SEMA7A) and sequestering it away from miR-28-5p (72).

Cancer susceptibility candidate 2 (CASC2) exerted tumor-suppressive effects through regulation of miR-24/MUC6 axis in pancreatic cancer cells (73). miR-24 knockdown or CASC2 overexpression suppressed pancreatic cancer cell proliferation, migration, invasion and promoted apoptosis. Mechanistically, CASC2 sponged miR-24 and relieved the repressive effects of miR-24 on MUC6 to suppress pancreatic cancer growth and progression (73).

LINC00657, an oncogenic lncRNA promoted the expression of PAK4 (p21 activated kinase-4) by protecting it from miR-433 (74). Tumor growth was significantly reduced in mice xenografted with LINC00657-silenced PDAC cells (74).

Long intergenic non-coding RNA for kinase activation (LINK-A) acted as an oncogenic lncRNA and promoted migratory and invasive potential of BxPC-3 via stimulation of ROCK1 (Rho associated coiled-coil containing protein kinase-1) (75).

Role of Long Non-Coding RNAs in Regulation of Drug Resistance in Pancreatic Cancer

HCP5, an lncRNA, stimulated the expression of hepatoma-derived growth factor (HDGF) by protecting it from targeting by miR-214-3p. HCP and HDGF promoted gemcitabine-resistant pancreatic cancer cells (76).

SBF2-AS1 knockdown inhibited proliferation, EMT and induction of apoptotic cell death in gemcitabine-resistant pancreatic cancer cells. SBF2-AS1 potentiated the expression of TWF1 by sponging away miR-142-3p (77).

The recent resurgence of public interest in herbal remedies, it was report that ginsenoside Rg3 effectively induced apoptosis in gemcitabine-resistant pancreatic cancer cells. Essentially, levels of CASC2 and PTEN were found to be considerably elevated in ginsenoside-treated pancreatic cancer cells (78).

Diagnostic Potential of LncRNAs

Because of better detection and high specificity in the liquid biopsy and tissue, there is increasing interest in exploring the potential of lncRNAs in cancer patients (79, 80). Profiling of the lncRNAs derived from extracellular vesicles has helped in the identification of a diagnostic signature for the detection of pancreatic ductal adenocarcinoma (81).

CONCLUDING REMARKS

Non-coding RNA biology has exploded in the recent era, and we have witnessed overwhelmingly increasing list of miRNAs and lncRNAs which regulated cancer onset and progression. Additionally, the concept of ceRNA has leveraged our understanding of the layered regulatory network of lncRNAs to another level. Cellular and molecular biologists are now focusing on identification of specialized lncRNAs which play crucial role in pancreatic cancer. Identification of most relevant lncRNAs will enable the development of mimics and antisense oligonucleotides for efficient treatment of pancreatic cancer.

AUTHOR CONTRIBUTIONS

SN, CM, and HK gathered and wrote the initial draft. AF, RB, MG, and WC input and edited the draft. AF designed the diagrams. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

The authors would like to thank Miss Maria Mariam for her assistance in English language editing.
Regulatory Networks. Cell Metab (2017) 25(2):400–11. doi: 10.1016/j.cmet.2016.11.016

12. Salehi S, Taheri MN, Azarpira N, Zare A, Behzad-Behbahani A. State of the Art Technologies to Explore Long Non-Coding RNAs in Cancer. J Cell Mol Med (2017) 21(12):3120–40. doi: 10.1111/jcmm.13238

13. Naganuma T, Hirose T. Paracaspase Formation During the Biogenesis of Long Non-Coding RNAs. RNA Biol (2013) 10(3):456–61. doi: 10.4161/rna.23547

14. Wu H, Yang L, Chen LL. The Diversity of Long Noncoding RNAs and Their Generation. Trends Genet (2017) 33(8):540–52. doi: 10.1016/j.tig.2017.05.004

15. Preker P, Almvg K, Christiansen MS, Valen E, Mapendano CK, Sandelin A, et al. PROMoter uPstream Transcripts Share Characteristics With mRNAs and are Produced Upstream of All Three Major Types of Mammalian Promoters. Nucleic Acids Res (2011) 39(16):7179–93. doi: 10.1093/nar/gkr370

16. Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, et al. Widespread Transcription at Neuronal Activity-Regulated Enrichers. Nature (2010) 465 (7295):182–7. doi: 10.1038/nature09033

17. Cabili M, Trapnell C, Goff L, Koziol M, Tazon-Vega B, Regev A, et al. Antisense Transcription in the Mammalian Transcriptome. Int J Biochem Cell Biol (2013) 45(1):5–10. doi: 10.1016/j.biocel.2012.06.020

18. Chen LL. Linking Long Noncoding RNA Localization and Function. Trends Biochem Sci (2016) 41(9):761–72. doi: 10.1016/j.tibs.2016.07.003

19. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, et al. Antisense Transcription in the Mammalian Transcriptome. Science (2005) 309(5740):1564–6. doi: 10.1126/science.1112009

20. Méle M, Mattiodi K, Mallard W, Shechner DM, Gerhardinger C, Rinn JL. Chromatin Environment, Transcriptional Regulation, and Splicing Distinguishing lincRNAs and mRNAs. Genome Res (2017) 27(1):27–37. doi: 10.1101/gr.214205.116

21. Zhang Y, Yang L, Chen LL. Life Without A Tail: New Formats of Long Noncoding RNAs. Int J Biochem Cell Biol (2014) 54:338–49. doi: 10.1016/j.biocel.2013.10.009

22. Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res (2017) 77(15):3965–81. doi: 10.1158/0008-5472.CAN-16-2634

23. Delas MJ, Hannon GJ. IncRNAs in Development And Disease: From Functions to Mechanisms. Open Biol (2017) 7(7):170121. doi: 10.1098/rsob.170121

24. Cipolla GA, de Oliveira JC, Salviano-Silva A, Lobo-Alves SC, Lemos DS, Oliveira LC, et al. Long Non-Coding RNAs in Vertebrate Embryonic Development Despite Rapid Sequence Evolution. Cell (2011) 147(7):1537–50. doi: 10.1016/j.cell.2011.11.055

25. Ulitsky I, Bartel DP. lincRNAs in Vertebrate Embryonic Development Despite Rapid Sequence Evolution. Cell (2011) 147(7):1537–50. doi: 10.1016/j.cell.2011.11.055

26. Ulitsky I, Bartel DP. lincRNAs: Genomics, Evolution, and Mechanisms. Cell (2013) 154(1):26–46. doi: 10.1016/j.cell.2013.06.020

27. Li N, Yang G, Luo L, Ling L, Wang X, Shi L, et al. LncRNA THAP9-AS1 Promotes EMT and Metastasis Of Pancreatic Cancer Cells. Cell Death Dis (2016) 7(1):e2786. doi: 10.1038/cddis.2016.178

28. Lou C, Zhao J, Gu Y, Li Q, Tang S, Wu Y, et al. LINC01559 Accelerates Pancreatic Cancer Cell Proliferation and Invasion by Upregulating miR-181c-5p. BioMed Pharmacother (2018) 100:130–7. doi: 10.1016/j.biopha.2018.03.005

29. Gao ZQ, Wang JF, Chen DH, Ma XS, Yang W, Zhe T, et al. Long Non-Coding RNA GAS5 Antagonizes the Chemoresistance of Pancreatic Cancer Cells Through Down-Regulation of miR-181c-5p. BioMed Pharmacother (2018) 97:809–17. doi: 10.1016/j.biopha.2017.10.157

30. Zhang M, Zhao Y, Zhang Y, Wang D, Gu S, Feng W, et al. lincRNA UCA1 Promotes Migration and Invasion in Pancreatic Cancer Cells via the Hippo Pathway. Biochim Biophys Acta Mol Basis Dis (2018) 1864(5 Pt A):1770–82. doi: 10.1016/j.bbadis.2018.03.005

31. Chen L, Zhang J, Chen Q, Ge W, Meng L, Huang X, et al. Long Noncoding RNA SOX2OT Promotes the Proliferation of Pancreatic Cancer by Binding to FUS. Int J Cancer (2019). doi: 10.1002/ijc.32827
61. Deng SJ, Chen HY, Ye Z, Deng SC, Zhu S, Zeng Z, et al. Hypoxia-Induced LncRNA HOTAIR Promotes Cancer Cell En ergy Metabolism in Pancreatic Adenocarcinoma Cells by Upregulating Hexokinase –2.

62. Guo J, Li J, Wang L, et al. Long Non-Coding RNA HOTAIR Contribute to Susceptibility of Pancreatic Cancer.

63. Ma Y, Hu M, Zhou L, Ling S, Li Y, Kong B, et al. Long Non-Coding RNA MACC1-AS1 Promoted Pancreatic Carcinoma Progression by Regulating the miR-205/MACC1-AS1 Axis.

64. Qi C, Xiaofeng C, Dongen L, Liang Y, Liping X, Yue H, et al. Long Non-Coding RNA MACC1-AS1 Promoted Pancreatic Carcinoma Progression Through Activation of PAX8/NOTCH1 Signaling Pathway. J Exp Clin Cancer Res (2019) 38(1):344. doi: 10.1186/s13046-019-1332-7

65. Jiang D, Xu L, Ni J, Zhang J, Cai M, Shen L. Functional Polymorphisms in LncRNA HOTAIR Contribute to Susceptibility of Pancreatic Cancer.

66. Moschos D, Vasilaki E, Tsouvala M, Karamanolis G, Katifelis H, Legaki E, et al. Association Between Genetic Polymorphisms in Long Non-Coding RNAs and Pancreatic Cancer Risk. Cancer Biomark (2019) 24(1):117–23. doi: 10.3233/CBM-181959

67. Han T, Jiao F, Hu H, Yuan C, Wang L, Jin ZL, et al. EZH2 Promotes Cell Migration and Invasion But Not Alters Cell Proliferation by Suppressing E-cadherin, Partly Through Association with MALAT1 in Pancreatic Cancer. Oncotarget (2016) 7(10):11194–207. doi: 10.18632/oncotarget.7156

68. Passaro F, De Martino I, Zambelli F, Di Benedetto G, Barbato M, D’Erchia AM, et al. YAP Contributes to DNA Methylation Remodeling Upon Mouse Embryonic Stem Cell Differentiation. J Biol Chem (2020) 2. doi: 10.1074/jbc.RA120105896

69. Testa G, Russo M, Di Benedetto G, Barbato M, Parisi S, Pirozzi F, et al. Bmi1 Inhibitor PTC-209 Promotes Chemically-Induced Direct Cardiac Reprogramming of Cardiac Fibroblasts Into Cardiomyocytes. Sci Rep (2020) 10(1):7129. doi: 10.1038/s41598-020-63992-8

70. Jiao F, Hu H, Yuan C, Wang L, Jiang W, Jin Z, et al. Elevated Expression Level of Long Noncoding RNA MALAT-1 Facilitates Cell Growth, Migration and Invasion in Pancreatic Cancer. Oncol Rep (2014) 32:2485–92. doi: 10.3892/or.2014.3518

71. Lei S, He Z, Chen T, Guo X, Zeng Z, Shen Y, et al. Long Non-coding RNA 00976 Promotes Pancreatic Cancer Progression Through OTUD7B by Sponging miR-137 Involving EGFR/MAPK Pathway. J Exp Clin Cancer Res (2019) 38(1):470. doi: 10.1186/s13046-019-1388-1394

72. Liu Y, Guo C, Li F, Wu L. LncRNA LOXLI1-AS1/miR-28-5p/SEMA7A Axis Facilitates Pancreatic Cancer Progression. Cell Biochem Funct (2019). doi: 10.1002/cbf.3449

73. Xu DF, Wang LS, Zhou JH. Long Non-coding RNA CAS2 Suppresses Pancreatic Cancer Cell Growth and Progression by Regulating the miR–24/MUC6 Axis. Int J Oncol (2019). doi: 10.3892/ijo.2019.4937

74. Bi S, Wang Y, Feng H, Li Q. Long Noncoding RNA LINC00657 Enhances the Malignancy of Pancreatic Ductal Adenocarcinoma by Acting as a Competing Endogenous RNA on microRNA-433 to Increase PAK4 Expression. Cell Cycle (2020) 1–16. doi: 10.1080/15384101.2020.1731645

75. Zhang M, Wang R, Zhao X, Lu L, Wang T. LncRNA LINK-A Regulates ROCK1 Expression in Early-Stage Pancreatic Adenocarcinoma. Exp Ther Med (2020) 19(3):1933–9. doi: 10.3892/etm.2019.8400

76. Liu Y, Wang J, Dong L, Xia L, Zhu H, Li Z, et al. Long Noncoding RNA HCP5 Regulates Pancreatic Cancer Gembatine (GEM) Resistance By Sponging Hsa-miR-214-3p To Target HDGF. Onco Targets Ther (2019) 12:8207–16. doi: 10.2147/OTT.S22703

77. Hua YQ, Zhu YD, Xie GQ, Zhang K, Sheng J, Zhu ZF, et al. Long Non-Coding SRFB2-AS1 Acting as a Competing Endogenous RNA to Sponge microRNA-142-3p to Participate in Gembatine Resistance in Pancreatic Cancer via Upregulating TWIF1 Aging (Albany NY) (2019) 11(20):8860–78. doi: 10.18632/aging.102307

78. Zou J, Su H, Zou C, Liang X, Fei Z. Ginsenoside Rg3 Suppresses the Growth of Pancreatic Cancer MG63 Cells. Biomed Pharmacother (2019) 125:109986. doi: 10.1016/j.biopha.2019.109986

79. Liu Y, Feng L, Wang L, Kong X, Li L, He J, et al. Circulating lncRNA ABHD11-CASC2 and Activating PTEN Signaling. J Biochem Mol Toxicol (2020), e22480. doi: 10.1002/jbt.22480

80. Liu Y, Feng W, Liu W, Kong X, Li L, He J, et al. Circulating IncRNA ABHD11-CASC2 and Activating PTEN Signaling. J Biochem Mol Toxicol (2020), e22480. doi: 10.1002/jbt.22480

81. Yu S, Li Y, Liao Z, Wang Z, Wang Z, Li Y, et al. Plasma Extracellular Vesicle Long RNA Promotes the Binding of Long Non-coding RNA MALAT1 Facilitates Cell Growth, Migration and Invasion in Pancreatic Cancer. Oncotarget (2017) 8(23):22482–91. doi: 10.18632/oncotarget.17305

82. Roberts DJ, Mijamomo S. Hoxainose II Integrates Energy Metabolism and Cellular Protection: Akting on Mitochondria and TORCing to Autophagy. Cell Death Differ (2019) 25(2):248–57. doi: 10.1038/cdd.2014.173

83. Jiang D, Xu L, Ni J, Zhang J, Cai M, Shen L. Functional Polymorphisms in LncRNA HOTAIOR Contribute to Susceptibility of Pancreatic Cancer. Cancer Cell Int (2019) 47. doi: 10.1186/s12935-019-0761-x

84. Moschos D, Vasilaki E, Tsouvala M, Karamanolis G, Katifelis H, Legaki E, et al. Association Between Genetic Polymorphisms in Long Non-Coding RNAs and Pancreatic Cancer Risk. Cancer Biomark (2019) 24(1):117–23. doi: 10.3233/CBM-181959

85. Han T, Jiao F, Hu H, Yuan C, Wang L, Jin ZL, et al. EZH2 Promotes Cell Migration and Invasion But Not Alters Cell Proliferation by Suppressing E-cadherin, Partly Through Association with MALAT1 in Pancreatic Cancer. Oncotarget (2016) 7(10):11194–207. doi: 10.18632/oncotarget.7156